课题基金 / 基金详情

EFFICACY AND SAFETY OF TIBOLONE IN POSTMENOPAUSAL WOMEN

EFFICACY AND SAFETY OF TIBOLONE IN POSTMENOPAUSAL WOMEN
替勃龙对绝经后女性的疗效和安全性
批准号：
3743867
负责人：
JOSEPH MORTOLA
金额：
$0.0万
依托单位：
BETH ISRAEL DEACONESS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/3743867
关键词：
chemoprevention disease /disorder prevention /control dosage drug quality /standard drug screening /evaluation female human subject human therapy evaluation osteoporosis postmenopause skeletal disorder chemotherapy

项目摘要

项目成果

JOSEPH MORTOLA的其他基金

相关文献

中文摘要
翻译
确定替勃龙预防糖尿病的最低有效剂量 绝经期骨质疏松症，并证明其疗效、安全性和 治疗剂量的药物的可接受性 适应症
英文摘要
To determine the minimum effective dose of Tibolone for prevention of menopausal osteoporosis and to demonstrate the efficacy, safety and acceptability of the medication at the therapeutic dose for this indication.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SAFETY AND EFFICACY OF RECOMBINANT HCG WITH PROFASI IN WOMEN UNDERGOING IVF
EFFICACY AND SAFETY OF TIBOLONE IN POSTMENOPAUSAL WOMEN
EFFICACY AND SAFETY OF TIBOLONE IN POSTMENOPAUSAL WOMEN
  • 批准号：
    5222186
  • 项目类别：
  • 资助金额：
    $0.0万
  • 财政年份：
    --
  • 负责人：
    JOSEPH MORTOLA
  • 依托单位：
    --
EFFICACY AND SAFETY OF 3 DOSES OF ESTERFIED ESTROGENS ON BONE MINERAL METABOLISM